Note: Descriptions are shown in the official language in which they were submitted.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
1
NEW SYNTHETIC ARGININE SUBSTITUTED PEPTIDES AND THEIR USE
Field of the invention
The present invention relates to new peptides and to use thereof, in
particular for
treatment and/or prevention of infections, inflammations and/or tumours.
Background art
Lactoferrin is a single chain metal-binding glycoprotein with a molecular
weight of 77
kd. It has been found that the structural domain of lactoferrin responsible
for the
bactericidal properties is a pepsin-cleaved fragment called lactoferricin (see
e. g.
Bellamy W., et al., Identification of the bactericidal domain of lactoferrin,
Biochim.
Biophys. Acta 1121: 130-136, 1992, and Bellamy W., et al., Antibacterial
spectrum of
lactoferricin B, a potent bactericidal peptide derived from the N-terminal
region of
bovine lactoferrin, J. Appl. Bact. 73: 472-479, 1992).
Lactoferrin receptors are found on many types of cells including monocytes and
macrophages, lectin-stimulated human peripheral blood lymphocytes, brushborder
cells, and tumour cell lines.
Several patent publications describe the possible use of lactoferrin for
treatment of
infections or inflammations. In WO 98/06425, e. g., it is disclosed that
lactoferrin and
lactoferricin can be used for treatment and prevention of infections,
inflammations and
tumours.
EP 629 347 describes an antimicrobial agent containing (A) lactoferrin
hydrolysate
and/or one or more of antimicrobial peptides derived from lactoferrins, and
(B) one or
more compounds selected from the group consisting of metal-chelating protein,
tocopherol, cyclodextrin, glycerine-fatty acid ester, alcohol, EDTA or a salt
thereof,
ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric
acid or a
salt thereof, chitosan, cysteine, and cholic acid as the effective components
thereof.
This antimicrobial agent is intended for treatment of products, and especially
for safely
treating e. g. food and medicines. The agent according to this publication is
thus a
new preservative. In the publication several peptide sequences are given and
some of
them resemble the peptides according to the invention, although there are
several
important differences described further below.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
2
US 5,304,633 discloses antimicrobial peptides isolated from hydrolysates of
human
and bovine lactoferrin. Isolation of peptides corresponding to amino acids 12
to 47,
and 17 to 41 of human lactoferrin are specifically disclosed.
JP 7145196 describes the preparation of antibiotic peptides by hydrolysis of
lactoferrin. The preparation of a peptide corresponding to amino acids 17 to
41 of
human lactoferrin is specifically described.
JP 8040925 discloses pharmaceutical compositions containing lactoferrin
derived
peptides and their use in the treatment of cornea damages, especially
keratitis.
Peptides corresponding to amino acids 17 to 41, 12 to 58, and 19 to 38, of
human
lactoferrin are specifically disclosed
JP 7274970 describes the recombinant production of antibacterial lactoferricin
derived
peptides, specifically a peptides corresponding to amino acids 18 to 42 of
human
lactoferrin is disclosed.
JP 8143468 describes lactoferrin derived peptides and their use as antiulcer
drugs, a
peptide corresponding to amino acids 19 to 33 of human lactoferrin is
specifically
disclosed.
WO 00/01730 describes peptides derived from human lactoferrin and their use
for
treatment of infections and inflammations.
EP 1 228 097 describes peptides derived from the immediate N-terminal end of
human lactoferrin and their use as microbial agents.
EP 1151009 describes peptides comprising a sequence corresponding to amino
acids
35 to 50 of human lactoferrin having antimicrobial and/or endotoxin
neutralizing
activity.
WO 2006/047744 describes immunomodulatory peptides derived from the N-terminal
part of human lactoferrin comprising at least 33 amino acids and being
substituted in
both the N- and C-terminus with four positively charged amino acids.
Summary of the invention
The object of the present invention is to provide new synthetic peptides which
can be
used for the same purposes as lactoferrin, lactoferricin or other lactoferrin
derived
peptides and which will have the same, or better, effects although having
production,
technical and/or biochemical advantages.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
3
The aim of the studies leading to the present invention was to design new
peptides
which should essentially be as efficient as, or preferably more efficient,
than human
lactoferrin, human lactoferricin and other lactoferrin derived peptides in
treatment and
prevention of infections, inflammations, tumours, wounds, and scars.
It was found that peptides formed of the sequences constituted of all or some
of the
amino acids 21-31 of human lactoferrin counted from the N-terminal end,
further
substituted with arginine containing peptides, have the desired properties.
According to the present invention, it is shown that the peptides designed
based on
the sequence constituted of amino acids 21-31 from the N-terminal end of human
lactoferrin, substituted with arginine containing peptides, have the desired
properties.
It has been shown that humans in their brush border membrane have receptors
which
can bind to human lactoferrin (see e. g. Lonnerdal B., Lactoferrin receptors
in
intestinal brush border membranes, Adv, Exp. Med. Biol. 1994, 357: 171-175).
It has
also been shown that bovine lactoferrin does not bind to these receptors. A
plausible
mechanism for the uptake of these new peptides in the human body is that the
peptides are taken up through binding to cellular receptors. However, the
invention is
in no way limited to this mechanism.
Thus, the present invention relates to new synthetic peptides and to
functionally
equivalent homologues or analogues thereof.
Furthermore, the invention relates to medicinal products and to food stuff,
especially
infant formula food, comprising said peptides.
The invention also relates to use of said peptides for the production of
medicinal
products for treatment and prevention of infections, inflammations and
tumours.
The peptides according to the invention are fungicidal and bactericidal, and
can thus
be used for other applications when substances with such properties are
desired.
They may for example be used as preservatives.
The characterising features of the invention will be evident from the
following
description and the appended claims.
Detailed description of the invention
Thus, the present invention relates to peptides designed based on the amino
acid
sequence of fragments of the protein human lactoferrin (hLF). The fragment of
hLF
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
4
that is used as a basis for the invention is constituted by the amino acids in
positions
21-31 of hLF, the sequence of which is:
Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg (SEQ ID NO: 1)
In the description single-letter or three-letter symbols are used to denote
the amino
acids. These symbols, which are well known to man skilled in the art, have the
following meaning: A = Ala = alanine, C = Cys = cysteine, D = Asp = aspartic
acid, E =
Glu = glutamic acid, F = Phe = phenylalanine, G= Gly = glycine, I- lie =
isoleucine, K =
Lys = lysine, M= Met = methionine, N = Asn = asparagine, P = Pro = proline, Q
= Gin
= glutamine, R = Arg = arginine, S = Ser = serine, T = Thr = threonine, V =
Val =
valine, W = Trp = tryptophan, Orn = Ornithine, Nle = Norleucine and X = Xaa =
a
variable amino acid. Ac and NH2 in some of the sequences denote an acetyl
(CH3CO-) group and an amino group, respectively, that have been used to modify
the
amino and the carboxy terminals of the peptides.
The N-terminal part of human lactoferrin contains an arginine rich sequence,
as
shown below for the sequence of amino acids 1-31 of human lactoferrin:
G ly-Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-
Cys-
-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg (SEQ ID NO:2)
The sequence Gly-Arg-Arg-Arg-Arg-Ser was identified as an important sequence
motif
and was used in the design of the peptides of the invention.
The present invention relates to peptides according to formula (I)
R1-Phe-X1-X2-X3-X4-X5-X6-X7-Lys-Val-Arg-X8-R2
Ia
R3 Formula (I)
wherein amino acid X1 is Gin or Ala, amino acid X2 is Trp or Leu, amino acid
X3 is
Gin, Ala, Orn, Nle or Lys, amino acid X4 is Arg, Ala or Lys, amino acid X5 is
Asn, Ala,
Orn or Nle, amino acid X6 is Met, Ala or Leu, amino acid X7 is Arg, Ala or
Lys,
amino acid X8 is Gly, Lys, Glu or Asp;
when X8 is Gly then R3 is Ser-(Arg)õ-X9 and the bond a is a peptide bond
between
the carboxyl group of Gly and the amino group of Ser;
when X8 is Lys then R3 is X9-(Arg)ue Ser and the bond a is an amide bond
between
the a-amino group in Lys and the carboxyl group in Ser; and
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
when X8 is Glu or Asp then R3 is Ser-(Arg),-X9 and the bond a is an amide bond
between the y-carboxyl group of Glu or the p-carboxyl group of Asp and the
amino
group of Ser;
amino acid X9 is either no amino acid or Gly;
5 and n is an integer from 1 to 10, preferably an integer from 2 to 6,
preferably an
integer from 4 to 6, or even more preferably an integer from 3 to 4;
R1 is either no amino acid, Cys or a peptide sequence selected from the
peptides
SEQ ID NO: 3 and N-terminally truncated fragments thereof including
G ly-Arg-Arg-Arg-Arg-Ser-Val-G I n-Trp-Cys-Ala-Val-Ser-G I n-Pro-G l u-Al a-Th
r-Lys-Cys,
Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Arg-Arg-Ser-Val-G I n-Trp-Cys-Ala-Val-Ser-G In-P ro-G l u-Ala-Th r-Lys-
Cys,
Arg-Arg-Ser-Val-G In-Trp-Cys-Ala-Va l-Ser-G I n-Pro-G lu-AI a-Thr-Lys-Cys,
Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-GI n-Pro-G lu-Ala-Thr-Lys-Cys,
Ser-Val-G In-Trp-Cys-Ala-Val-Ser-Gln-Pro-G lu-Ala-Thr-Lys-Cys,
Val-Gln-Trp-Cys-Ala-Val-Ser-Gin-Pro-Glu-Ala-Thr-Lys-Cys,
G In-Trp-Cys-Ala-Val-Ser-GI n-Pro-G lu-Ala-Thr-Lys-Cys,
Trp-Cys-Ala-Val-Ser-Gin-Pro-G lu-Ala-Thr-Lys-Cys,
Cys-Ala-Val-Ser-Gin-Pro-G lu-Ala-Thr-Lys-Cys,
Ala-Val-Ser-GI n-Pro-Glu-Ala-Thr-Lys-Cys,
Val-Ser-Gin-Pro-Glu-Ala-Thr-Lys-Cys,
Ser-Gin-Pro-G lu-Ala-Thr-Lys-Cys,
Gin-Pro-G lu-Ala-Thr-Lys-Cys,
Pro-G l u-Ala-Thr-Lys-Cys ,
Glu-Ala-Thr-Lys-Cys,
Ala-Thr-Lys-Cys,
Thr-Lys-Cys,
and
Lys-Cys,
Preferably R1 is either no amino acid, Cys or a peptide sequence selected from
the
peptides SEQ ID NO: 11 and N-terminally truncated fragments thereof including
Ser-Val-G In-T rp-Cys-Ala-Val-Ser-G I n-Pro-G l u-Ala-Thr-Lys-Cys,
Val-G I n-Trp-Cys-Ala-Val-Ser-G l n-Pro-G lu-Ala-Thr-Lys-Cys,
Gin-Trp-Cys-Ala-Val-Ser-Gln-Pro-G lu-Ala-Thr-Lys-Cys,
Trp-Cys-Ala-Val-Ser-Gln-Pro-G lu-Ala-Thr-Lys-Cys,
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
6
Cys-Ala-Val-Ser-Gln-Pro-G lu-Ala-Thr-Lys-Cys,
Ala-Val-Ser-Gln-Pro-G Iu-Ala-Thr-Lys-Cys,
Val-Ser-Gin-Pro-G lu-Ala-Thr-Lys-Cys,
Ser-G l n-Pro-G lu-Ala-Thr-Lys-Cys,
Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Pro-G Iu-Ala-Thr-Lys-Cys,
Glu-Ala-Thr-Lys-Cys,
AIa-Thr-Lys-Cys,
Thr-Lys-Cys,
and
Lys-Cys,
R2 is either no amino acid, Pro or a peptide sequence selected from SEQ ID
NO:4
and C-terminally truncated fragments thereof including
Pro-Pro-Val-Ser-Cys-l le-Lys-Arg,
Pro-Pro-Val-Ser-Cys-Ile-Lys,
Pro-Pro-Val-Ser-Cys-I le,
Pro-Pro-Val-Ser-Cys,
Pro-Pro-Val-Ser,
Pro-Pro-Val, and
Pro-Pro;
The above peptide sequences defining R2 thereby being represented by SEQ ID
NO:
4 or C-terminally truncated fragments thereof.
In one preferred embodiment X8 is Gly and R3 is Ser-(Arg)ue X9 and the bond a
is a
peptide bond between the carboxyl group of Gly and the amino group of Ser.
In another preferred embodiment X8 is Lys and R3 is X9-(Arg),,-Ser and the
bond a is
an amide bond between the c-amino group in Lys and the carboxyl group in Ser.
In another preferred embodiment X8 is Glu and R3 is Ser-(Arg)ue X9 and the
bond a is
an amide bond between the y-carboxyl group of Glu and the amino group of Ser.
In other preferred embodiments amino acid X1 is Gln, X2 is Trp, X3 is Gln or
Lys, X4
is Arg, X5 is Asn or Ala, X6 is Met, and/or X7 is Arg.
In another preferred embodiment RI is either no amino acid or the peptide
sequence
AIa-Thr-Lys-Cys.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
7
In yet another preferred embodiment R2 is either no amino acid or the peptide
sequence Pro-Pro-Val-Ser-Cys-Ile-Lys-Arg.
In one preferred embodiment the present invention provides purified peptides
comprising SEQ ID NO: 12 (Phe-Gln-Trp-X3-Arg-X5-Met-Arg-Lys-Val-Arg-Gly-Ser-
Arg-Arg-Arg-Arg-Gly), wherein X3 is Gin or Lys and X5 is Asn or Ala, and
wherein the
peptide is SEQ ID NO: 5, 6, 7, 8, 9, or 10.
When present, it may be advantageous to replace the amino acid Cys by an
acetamidomethyl-cysteine in order to avoid that the peptide forms a disulphide
bridge
with another peptide comprising a cysteine, and/or an intermolecular
disulphide bridge
if the peptide comprises two Cys residues.
According to one preferred aspect of the invention the carboxy terminal end of
the
peptide has been capped, i. e. the free COOH at the carboxy terminal end has
been
transformed into CON H2.
According to another preferred aspect of the invention the amino terminal end
of the
peptide has been capped, i. e. the free NH2 group at the amino terminal end
has been
transformed into the amide CH3CONH- (AcNH-).
When the peptides are branched one or both of the amino terminal ends of the
peptide can be capped. When the peptides are branched one or both of the
carboxy
terminal ends of the peptide can be capped.
According to yet another preferred aspect of the invention both the carboxy-
terminal
and the amino-terminal ends of the peptide have been capped.
The advantage of the capped versions is that N- and C-terminal amino acids of
these
peptides are neutral and uncharged and thus has changed electrostatic
properties.
Assuming that the receptors bind the corresponding sequences of human
lactoferrin
where there are no N- and C terminal charges, the capped peptides should bind
better
as they in this respect resemble the native protein more than uncapped
peptides.
Preferred peptides of the invention are:
Ac-Phe-Gln-Trp-G In-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
1
Gly-Arg-Arg-Arg-Ser;
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
8
Ac-Phe-G I n-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
GIy-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-N H2
GIy-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-G I n-Trp-Lys-Arg-Asn-Met-Arg-Lys-Va I-Arg-Lys-NH2
I
GIy-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gin-Trp-Lys-Arg-Al a-Met-Arg-Lys-Val-Arg-Lys-NH2
GIy-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-G I n-Trp-G I n-Arg-Asn-Met-Arg-Lys-Va I-Arg-Lys-NH2
1
Ac-G ly-Arg-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-G In-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
I
Ac-GIy-Arg-Arg-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-GIu-NH2
Ser-Arg-Arg-Arg-Arg-GIy-NH2i
Ac-Phe-Gln-Trp-G In-Arg-Ala-Met-Arg-Lys-Val-Arg-GIu-NH2
Ser-Arg-Arg-Arg-Arg-GIy-NH2i
Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Vai-Arg-GIu-NH2
Ser-Arg-Arg-Arg-Arg-GIy-NH2;
Ac-Phe-G In-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-GIu-NH2
Ser-Arg-Arg-Arg-Arg-GIy-NH2;
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
9
Ala-Thr-Lys-CysM-
-Phe-GI n-Trp-G I n-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-I le-
Lys-Arg
Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-G In-Trp-Gin-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-
Lys-Arg
Gly-Arg-Arg-Arg-Arg-Ser;
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-G In-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2
I
GIy-Arg-Arg-Arg-Arg-Ser;
AIa-Thr-Lys-CysM-
-Phe-G In-Trp-Lys-Arg-AIa-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-I ie-
Lys-Arg
GIy-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Lys-Arg-AIa-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-Ile-
Lys-Arg
G Iy-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-G In-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-I Ie-
Lys-Arg-NH2
I
Ac-GIy-Arg-Arg-Arg-Arg-Arg-Ser
AIa-Thr-Lys-CysM-
-Phe-G In-Trp-Lys-Arg-AIa-Met-Arg-Lys-Val-Arg-Lys-NH2
I
G Iy-Arg-Arg-Arg-Arg-Ser;
AIa-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-AIa-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-Ile-Lys-
Arg
Ser-Arg-Arg-Arg-Arg-GIy-NH2;
Ac-P he-G I n-T rp-G In-Arg-AIa-Met-Arg-Lys-Val-Arg-G I u-Pro- Pro-Val-Ser-
CysM-I le-Lys-Arg
I
Ser-Arg-Arg-Arg-Arg-GIy-N H2i
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-G I n-Arg-Ala-Met-Arg-Lys-Val-Arg-GIu-NH2
I
Ser-Arg-Arg-Arg-Arg-Gly-NH2;
5
Ala-Thr-Lys-CysM-
-Phe-Gin-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-I le-Lys-
Arg
Ser-Arg-Arg-Arg-Arg-GIy-N H2i
Ac-Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Giu-Pro-Pro-Val-Ser-CysM-Ile-
Lys-Arg
Ser-Arg-Arg -Arg-Arg-GIy-N H2i
Ac-Phe-Gin-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Giu-NH2
Ser-Arg-Arg -Arg-Arg-Arg-Arg-GIy-NH2
AIa-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-AIa-Met-Arg-Lys-Vai-Arg-GIu-NH2
I
Ser-Arg-Arg-Arg-Arg-GIy-NH2;
Ac-Phe-GIn-Trp-G I n-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-G ly-
N H2i
(SEQ ID NO: 5)
AIa-Thr-Lys-CysM-
-Phe-GIn-Trp-G In-Arg-Asn-Met-Arg-Lys-Vai-Arg-G Iy-Ser-Arg-Arg-Arg-Arg-GIy-
NH2;
(SEQ ID NO: 6)
Ac-Phe-GIn-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-GIy-N
H2i
(SEQ ID NO: 7)
AIa-Thr-Lys-CysM-
-Phe-GIn-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-GIy-Ser-Arg-Arg-Arg-Arg-GIy-NH2;
(SEQ ID NO: 8)
Ac-Phe-GIn-Trp-Lys-Arg-AIa-Met-Arg-Lys-Val-Arg-GIy-Ser-Arg-Arg-Arg-Arg-GIy-
NH2;
(SEQ ID NO: 9)
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
11
Ala-Thr-Lys-CysM-
-Phe-G In-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-GIy-NH2
i
(SEQ ID NO: 10)
CysM is acetamidomethyl-cysteine.
Where the N-terminally and/or C-terminally capped form of a peptide has been
given,
it is also possible, according to the invention, to use the un-capped forms.
Where the N-terminally and/or C-terminally un-capped form of a peptide has
been
given, it is also possible, according to the invention, to use the capped
forms.
The sequences GIy-Arg-Arg-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Arg-Arg-Ser,
GIy-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Ser, Ser-Arg-Arg-Arg-Arg-Arg-Arg-Gly,
Ser-Arg-Arg-Arg-Arg-Arg-Gly and Ser-Arg-Arg-Arg-Arg-Gly are positively charged
under physiological conditions and are capable of strong and specific
interactions with
receptors. They are therefore an important part of the peptides according to
the
invention.
The advantage of the peptides according to the invention is that they comprise
the
part of the lactoferricin fragment of the human lactoferrin protein, or a
modified version
thereof, which the inventors have found to be active with regards to the
invention.
In some cases only the capped form of a sequence has been given in the
appended
sequence listing. However, it is also possible, according to the invention, to
use the
non-capped forms.
Further substitution of active fragments of hLF with an Arg containing peptide
resulting
in the peptides of the present invention has been shown to provide peptides
with
improved properties compared to other known peptides derived from hLF.
The peptides according to the invention are suitable for treatment and/or
prevention of
infections, inflammations, tumours, pain, wounds and scars. The term
"treatment"
used herein refers to curing, reversing, attenuating, alleviating, minimising,
suppressing or halting the deleterious effects of a disease state, disease
progression
or other abnormal condition, and the term "prevention" used herein refers to
minimising, reducing or suppressing the risk of developing a disease state or
progression or other abnormal or deleterious conditions.
The infections treatable with the peptides or medicinal products according to
the
invention include infections caused by all kinds of pathogens, such as
bacteria,
viruses, fungi, etc.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
12
It is also possible to treat different types of inflammations. Inflammation is
a complex
phenomenon marked La, by abnormal "redness" and swelling of tissues and
organs,
pain and heat in affected areas, capillary dilation, leucocyte infiltration,
etc.
Inflammation is primarily caused by exposure to bacterial and other noxious
agents
and physical injury. Inflammation has many forms and is mediated by a variety
of
different cytokines and other chemical signals. These mediators of
inflammation
include tumour necrosis factor-a (TNF-(x), interleukin-1 (IL-1), interleukin-6
(IL-6),
interleukin-8 (IL-8), and various colony-stimulating factors (CSFs).
As stated above, the peptides according to the invention are also suitable for
treatment of tumours.
The peptides according to the invention may either be used as they are or be
included
in a medicinal product or a pharmaceutical preparation. The medicinal product
or a
pharmaceutical preparation according to the invention may also comprise
substances
used to facilitate the production of the pharmaceutical preparation or the
administration of the preparations. Such substances are well known to people
skilled
in the art and may for example be pharmaceutically acceptable adjuvants,
carriers
and preservatives.
The peptides according to the invention may either be formulated for oral
administration, systemic administration, parenteral administration, local
administration
or topical administration.
The peptides or medicinal products according to the invention can be
administered to
a patient either orally, systemically, parenterally, locally or topically. The
term "patient"
used herein relates to any person at risk for or suffering from a disease
state, disease
progression or other abnormal or deleterious condition.
The systemic administration is suitable e. g. for treatment of urinary tract
infection,
colitis and tumours. The systemic administration can be undertaken by oral,
nasal,
intravenous, intraartery, intracavitary, intramuscular, subcutaneous,
transdermal,
suppositories (including rectal) or other routes known to those of skill in
the art. Oral
administration is preferred.
The local administration is suitable e. g. for treatment of skin infections,
all infections
and inflammations in mucosal membranes etc. The local administration can be
undertaken by topical, oral, nasal, vaginal or oropharyngeal route. For
treatment of
local infections or inflammations in the skin or mucosal membranes the
peptides or
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
13
medicinal products according to the invention may e. g. be included in a gel,
a cream,
an ointment, or a paste.
In the method according to the invention an effective amount of a peptide
according to
the invention is administered to a patient. The term "effective amount" used
herein
relates to an amount sufficient to treat or prevent a disease state, disease
progression
or other abnormal or deleterious conditions.
The peptides or medicinal products and methods according to the invention are
particularly well suited for treatment and/or prevention of urinary tract
infection and
colitis, but several other inflammatory and infectious diseases are also
treatable
according to the present invention, such as inflammatory bowel diseases,
rheumatoid
arthritis, conditions caused by the virus HIV-1, conditions caused by the
virus CMV,
and conditions caused by fungi, e.g. Candida species such as Candida albicans
and
Candida krusei, Aspergillus and Cryptococcus neoformans. This listing is in no
way
limiting the scope of the invention.
The peptides, medicinal products and methods according to the invention are
also
well suited for preventive medical care by reducing the risk of developing
urinary tract
infection or other inflammatory or infectious diseases in patients with an
increased risk
of attracting such complications.
The peptides of the present invention are suited for are anti-inflammatory and
immunomodulatory therapies, exemplified but not limited to:
1) Generally, treatment of inflammation and/or medical condition resulting
from
inflammation, and specifically,
2a) Intestine; Morbus Crohn, Colitis, Ulcerative colitis,
2b) Joints; Rheumatoid arthritis, Arthritis, Arthrosis, Localized disorders of
muscles
including muscle spasm, muscle tear, muscle injury, muscle strain, muscle
sprain,
2c) Dermatology; Psoriasis, Eczema (excema), Dermatitis, Acne
2d) Heart; Pericarditis, Endocarditis Cardiac insufficiency,
2e) Pain; (further specified under 2f below).
2f) Nervous system; Alzheimer, Multiple Sclerosis, Carpal tunnel syndrome,
Disc
herniation, Cervical rhizopathy, Bells palsy, Acute spinal cord injury, Spinal
cord
compression, Spinal stenosis, Postherpetic neuralgia, Viral encephalitis,
Viral
meningitis, Menieres disease, Polio and postpolio complications, Chronic
Inflammatory Demyelinating Polyneuropathy, Polyneuropathy, Trigminal
neuralgia,
Chronic epileptic disorders,
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
14
2g) Sensory organs; Glaucoma
2h) Mucosal surfaces (inflammation as a result of chemo/radiation therapy),
2i) Allergy,
2j) Autoimmune diseases
The peptides of the invention are further suited for prevention and treatment
of
wounds and scars in connection with conditions and procedure, exemplified but
not
limited to:
3a) surgical procedures on various tissues such as skin, muscles, tendons,
nervous
tissue, blood vessels, and at different locations of the body such as eyes,
ears, vocal
cord, hand, spinal cord, intra-abdominal cavity, intra-thoracic cavity, intra-
cranial
cavity, oral cavity, gynecological procedures, endometrios, phimosis,
3b) acne
3c) hypertrophic scars & keloids,
3d) pleuritis,
3e) peritoneal dialysis,
The peptides of the invention are further believed to have anti-angiogenetic
effects
and are therefore suited for treatment of :
4a) Cancer
4b) Rheumatoid arthritis
The peptides of the invention have anti-infectious effects, and are suited for
the
prevention and treatment of:
5a) Antibacterial effects:
Upper and lower respiratory tract (tonsillitis, sinusitis etc.)
Infections of the eye (e.g. conjunctivitis)
Urinary tract infections
Sexually transmitted diseases (including antimicrobial coating of condomes)
Genital tract including vaginosis, vaginitis, cervicitis, endometritis, PID
Gastrointestinal tract infections (systemic infections initiated in the GI)
Central nervous system infections
Infections of the skin (including staphylococci, for instance MRSA,
nosocomial,
wounds, burns), muscle, joints (e.g. septic arthritis), bone and hemopoietic
system
Infections related to the mouth, including parodontitis, gingivitis
5b) Antiviral effects:
Upper and lower respiratory tract
Sexually transmitted diseases
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
Gastrointestinal tract infections (systemic infections initiated in the GI)
Central nervous system infections
5c) Antifungal effects:
Upper and lower respiratory tract (such as aphthae, mucocutanous candidiasis)
5 Genitourinary tract, such as vulvovaginal candidiasis, balanitis,
Gastrointestinal tract infections (systemic infections initiated in the GI)
Central nervous system infections
Infections of the skin (such as mucocutanous candidiasis)
The peptides, medicinal products and methods according to the invention may
either
10 be used alone, in combination with each other or in combination with
conventional
therapy.
According to the present invention it is also possible to include the
peptides, in an
effective amount, in any kind of food or beverage intended to reduce
infections and/or
inflammations in patients running an increased risk of such conditions due to
an
15 underlying disease, a low birth weight or a medical treatment. For example,
it is
possible to include the peptides, in an effective amount, in an infant formula
food
intended to inhibit harmful effects of bacteria, such as weight loss caused by
inflammation induced by bacteria, viruses or fungi in infants. When the
peptides
according to the invention is to be used in food stuffs, e. g. for nutritional
purposes, it
is especially preferred to use peptides of natural origin.
Since the peptides according to the invention have antimicrobial effects they
can also
be used as preservatives in different food stuffs and medicinal products such
as gels,
creams, ointments, pastes, solutions, emulsions etc.
The invention will now be further explained in the following examples. These
examples are only intended to illustrate the invention and should in no way be
considered to limit the scope of the invention.
Brief description of the drawings
Figure 1. Growth inhibition of E.coli in the presence of HLBDarg1 and a 23-
a.a. long
peptide (amino acids 18 to 40 of hLF). Using a peptone medium (1%) the
microplate
was incubated over night and read spectrophotometrically at 650 nm. As can be
seen
a concentration of 12.5 g/ml totally reduced the growth.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
16
Figure 2. A) The number of S.aureus located in the joints of peptide-treated
and
vehicle treated animals. B) The distribution of animals with a scoring of 3 or
more (the
most severe inflammation and/or erosion of joint tissue was scored as 5, and
no
histological changes as 0). A dose of 2x104 S.aureus and 100 g of peptide
(HLBDarg1) were injected.
Figure 3. Effects of peptide treatment in Candida skin infection (quadruple
spots for
each peptide). The treatment dose was 400 g per infected area. The arginine
containing peptide reduced C.albicans to a higher degree than a longer peptide
sequence based on the antimicrobial region in LF (peptide 25 a.a. = peptide
corresponding to amino acids 16-40 of hLF).
Figure 4. Inhibitory activity of a lactoferrin-derived (HLBD1 Arg rak) peptide
on IL-1-
induced IL-6 (A) or PAI-1 (B) production in MeT-5A cells. Indicated peptide
concentrations were added to cells in triplicate (n=3) immediately after the
addition of
IL-1, the cell supernatants were collected after 3 hours (in A) or 6 hours (in
B) of
incubation and analyzed for IL-6 (in A) or PAI-1 (in B) by quantitative ELISA.
The
results are expressed in relation to the IL-6 level (288 pg/ml) or PAI-1 level
(18.3
ng/ml) obtained without any peptide added, respectively. Statistical
differences were
determined by two-sided Student's t-test (* p:5 0.05; ** ps 0.01; *** sp0.005;
****
sp0.001).
Figure 5. Dose-inhibitory activity of a lactoferrin-derived peptide (HLBD1 Arg
rak) on
LPS-induced TNF-a secretion in human monocyte derived macrophage cell line THP-
1 cells. Indicated peptide concentrations were added to cells in triplicate
(n=3) 30 min
after the addition of LPS (0.1 ng/ml). TNF-a levels at 6 h after the
stimulation were
measured by ELISA (R&D Systems, Minneapolis, MN). The results are expressed in
relation to TNF-a levels (290 pg/ml) obtained without any peptide added.
Statistical
differences among genotypes were determined by two-sided Student's t-test (*
p:5
0.05).
Figure 6. Dose-inhibitory activity of lactoferrin-derived peptides on IL-1(3-
induced IL-6
(A) or PAI-1 (B) production in MeT-5A cells. Indicated peptide concentrations
were
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
17
added to cell in triplicate (n=3) immediately after the addition of IL-1 R,
the cell
supernatants were collected after 3 hours (in A) or 6 hours (in B) of
incubation and
analyzed for IL-6 (in A) or PAI-1 (in B) by quantitative ELISA. The results
are
expressed in relation to the IL-6 level (1770 pg/ml) or PAI-1 level (63.0
ng/ml)
obtained without any peptide added. Statistical differences were determined by
two-
sided Student's t-test (* p:5 0.05;). = = HLBDarglrak, A= PXL11, X = PXL12, ^
_
PXL13, = = PXL14.
Figure 7. Dose-inhibitory activity of of lactoferrin-derived peptides on LPS-
induced
TNF-a secretion in human monocyte derived macrophage cell line THP-1 cells.
Indicated peptide concentrations were added to cells in triplicate (n=3) 30
min after
the addition of LPS (0.1 ng/ml). TNF-a levels at 6 h after the stimulation
were
measured by ELISA (R&D Systems). The results are expressed in relation to TNF-
a
levels (273-775 pg/ml) obtained with peptide added at 10 pg/ml. Statistical
differences
were determined by two-sided Student's t-test (* p:5 0.05;). = = HLBDarg1rak,
A= PXL11, X = PXL12, ^ = PXL13, 0 = PXL14.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
18
Examples
Example 1. Antimicriobial assay
Arg-Arg-Arg-Arg- or Arg-Arg-Arg- containing peptides (Table 1) have been
analysed
by an antimicrobial assay using E.coli, S.aureus and C.albicans as test
microorganisms.
Washed cells were suspended in 1 % Bactopeptone (BP)(Difco, USA). The
concentration of bacterial or fungal cells was spectrophotometrically
adjusted.
Peptides serially diluted in BP by twofold steps were added in duplicate or
triplicate to
the wells of a microtiterplate (200 l per well). The bacterial or yeast cell
solutions
were added in 10 l volumes to give a final concentration of approximately 2 x
105
cells per ml. The concentration of the stock solution was always checked by
viable
counts. The microplate was incubated at 37 C in a humid chamber for 2 h unless
otherwise stated. Five l were taken from each well and added as a drop onto a
blood
agar plate and incubated over night at 37 C.
The concentration of lactoferrin or peptide causing a 99% reduction of the
inoculum
was defined as the MMCg9.
The microbicidal activity of the peptides showed that all peptides were better
than the
natural sequence amino acids 1-31 (HLBD31) except for HLBDarg2 (Table 2). In
this
peptide the Arg-Arg-Arg-Arg-Arg sequence was linked to phenylalanine from the
amino-terminal side via a spacer (three glycine residues).
In Figure 1 the growth inhibition of HLBDarg1 was compared with a native
lactoferrin-
derived peptide HLBD2 consisting of amino acids 18 to 40, A much stronger
antimicrobial activity was recorded for HLBDargl in this medium which strongly
reduces the antimicrobial activity of many other LF derived peptides.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
1.9
2
z
m lx m X
z Y ? Y
0 - lx -
U 0
> of >
wa
_ = a I 04 z IN
z C z z z z W(L
Y-0) 0 Y-W -W -aOY -(n Y-cnY -(nw -coY -co
Of w Ir w Er x Er w m w w lx lx Of Of lx a lx lx
> lx > > > lx> lx> lx> Of > > lx> lx> > lx
w Y Y Y Y Y w Y w Y Y w Y x Y Y w
ir w lx lx C9lx Ww lxl w lxlx W- Of lxlx lx lx
a M 2 2 2 0.M 0 0W 22 Of 2 x2 It
z z z z a a a a zz (Dz x19 z It
lx lx lx lx C~ it w Q~ tea!
dCl Cl d C'1 0 Y a co CO 0 by a o
a a a a a CY C1 a 0 0 a a a
E LL IL U- W W W W U W W U LL U
W cs U U U U E E V U U V
< 0< Q < UQ Q < <
(~ Y a
v 0 I- > F-
< CO <
I l m
W a>
lx l U
Of d'
w 0 0
N E
0
CL
E
`, e- e- N in
r
Q Im co v Q. w
d a a a a s a N M
N =~- 0 C3 o a a C3 0 a r C e'_- '- ems- r v_-
m m m m CO m ta m a, m J J J J
~ a = __ _ _ =Q =a z x x x a U
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
Table 2
MMC,9, lag/ml
C. albicans S. aureus E.coli
5
peptide 2 h 24 h 2 h 24 h 2 h 24 h
HLBDargl 6.3 10 12 19 17 3.1
HLBDarg5 12 12 25 25 25 6
HLBDargloptC 12 21 25 25 19 6
HLBDargloptC(K24) 550 550 16 12 12 6
HLBD2optCargl 12 25 25 25 25 12
HLBDarglrak ND ND 12 19 12 6
HLBDarg2 >100 >100 >100 >100 >100 >100
HLBD31 25 38 100 100 >100 50
*ND= not determined
Example 2. Staphylococcus aureus joint infection.
Mice. 5 to 8-week old mice were obtained from B&K (Sollentuna, Sweden) and
maintained in the animal facility of the Department of Rheumatology,
University of
Goteborg. They were housed 10 per cage under standard conditions of
temperature,
and light and fed standard chow and water ad libitum.
Bacterial strain and infection. S.aureus strain AB-1 was used. The bacteria
were
injected into the both knee joints (synovial space) of the hind paw.
Immediately before
injection, bacteria and peptide or vehicle only were mixed. A dose of 2x104
S.aureus
and 100.tg of peptide (HLBDarg1) were injected. The knee of the right hind paw
was
used as positive control. Also some animals were injected with peptide
solution only.
The animals were killed at day 3 after infection and the knee joints were
fixed in
formaline and decalcified for histological evaluation. The number of bacteria
present in
the left joint was analysed by culturing (cotton swab of joint fluid after
removal of skin).
The numbers of S. aureus in the joint were higher in the vehicle treated group
although no statistical significance was established (Figure 2). The blind
scoring of the
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
21
joints revealed significant differences between peptide-treated and vehicle
treated
animals. Thus the peptide appeared to reduce the severity of the
Staphylococcus-
induced arthritis.
Example 3. Candida albicans skin infection
Candida albicans. The yeast cells (ATCC64549) were incubated over night in
Sabourad broth at 23 C. The cells were washed in phosphate buffer (10 mM, pH
7.4)
and adjusted to a concentration of 2x1010im1.
Skin infection and peptide treatment. Mice were treated with C. albicans on a
shaved
area (2x108 yeast cells per spot) by gentle rubbing a volume of 10 p1 with a
blunt
plastic rod during anaesthesia. The following day anaesthetized mice were
treated
with 10 or 20 .tl of a peptide solution or vehicle (phosphate buffer) by
applying the
volume onto the infected spots. The solution was allowed to dry. After 4 h the
treatment was repeated. The day after the animals were killed. Viable counts
were
performed on washings, obtained from the treated areas by using a metal ring
placed
over the spot and gentle rubbing in the presence of 100 pl of phosphate buffer
containing Triton-x 100 (0.01 %). At most three different concentrations of
the peptide
were used, starting with 400, 100, and 25 g per spot. Although a high
variability was
obtained (quadruple spots for each concentration), a clear reduction of colony-
forming
units (CFU) is obtained with the three peptides (Table 3). The results
obtained with
400 g are presented in Figure 3.
Table 3.
Candida albicans
peptide no. of CFU (mean SE) CFU(mean SE) p value
experiments treatment vehicle
H LBDarg 1 3 40 10 166 33 0.0066
HLBDarglrak 2 105 28 414 60 0.0004
HLBDarg5 1 12 8.3 43 3 0.024
1 mg per spot
Example 4. In vitro anti-inflammatory and fibrinolytic effect
The MeT-5A cell line corresponding to normal human mesothelial cells was
maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum
(FBS; PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF; AMS
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
22
Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA
Laboratories GmbH) and 870 nM human recombinant insulin (Sigma). The cells
were
induced by addition of recombinant IL-1 (R&D Systems), 0.1 or 0.5 ng/ml in the
case
of the IL-6 or PAI-1 assay, respectively, into the medium specified above
except of
containing 5% heat inactivated FBS. The given concentration of peptide
HLBD1 Arg rak was added immediately after stimulation by IL-1.
IL-6 production was measured 3 hours after induction by quantitative
immunoassay
ELISA using human monoclonal anti-IL-6 antibody (R&D Systems).
PAI-1 levels were measured 6 hours after induction by commercially available
ELISA
kit (Tint-Eliza PAI-1, Trinity Biotech).
The results are expressed in relation to the IL-6 (288 pg/ml) or PAI-1 levels
(18.3
ng/ml) obtained without any peptide added.
The results (Figure 4) indicate that IL-6 and PAI-1 production in mesothelial
cells is
significantly down regulated by the peptide.
Example 5. In vitro anti-inflammatory effect
The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was
maintained in RPMI 1640 (PAA Laboratories GmbH) supplemented with 10% fetal
bovine serum (FBS; PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES
(PAA). The cell density was adjusted to 1 x106 cells/ml and 500 pl of the cell
suspension was added to 24-well cell culture plates (Sarstedt). The cells were
treated
with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to
differentiate the monocytes into macrophage-like cells. After 48 hours the
cells were
stimulated by addition of 0.1 ng/ml LPS (E. coil serotype 055:85; Sigma) into
the
medium specified above except of containing 5% heat inactivated FBS. The given
concentration of peptide HLBD1 Arg rak was added 30 minutes after addition of
LPS.
The cell supernatants were collected after 6 hours of incubation, centrifuged
and
analyzed for TNF-a production by ELISA (R&D Systems).
The results (Figure 5) of the experiment demonstrate that TNF-a production in
human
monocyte derived macrophages is significantly down regulated by the peptide.
Example 6. In vitro anti-inflammatory and fibrinolytic effect
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
23
The MeT-5A cell line corresponding to normal human mesothelial cells was
maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum
(FBS; PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF; AMS
Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA
Laboratories GmbH) and 870 nM human recombinant insulin (Sigma). The cell
density
was adjusted to 1.6x105 cells/ml and 100 pl of the cell suspension was added
per well
to 96-well cell culture plates (Sarstedt). The cells were incubated for 48
hours to allow
cells to attach and grow to confluence. After 48 hours the cells were induced
by
addition of recombinant IL-1 (3 (R&D Systems), 0.1 or 0.5 ng/ml in the case of
the IL-6
or PAI-1 assay, respectively, into the medium specified above except of
containing
5% heat inactivated FBS. The given concentrations of the different peptides
were
added immediately after stimulation by IL-1 R.
The cell supernatants were collected after 3 or 6 hours of incubation and
analyzed for
IL-6 or PAI-1 by ELISAs specific for IL-6 (R&D Systems) or for PAI-1 (Tint-
Eliza PAI-1,
Trinity Biotech), respectively.
The results (Figure 6) indicate that IL-6 and PAI-1 production in mesothelial
cells is
significantly down regulated by the peptides.
Example 7, In vitro anti-inflammatory effect
The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was
maintained in RPMI 1640 (PAA Laboratories GmbH) supplemented with 10% fetal
bovine serum (FBS; PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES
(PAA). The cell density was adjusted to 1x10' cells/ml and 100 pi of the cell
suspension was added per well to 96-well cell culture plates (Sarstedt). The
cells were
treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48
hours to
differentiate the monocytes into macrophage-like cells. After 48 hours the
cells were
stimulated by addition of 0.1 ng/ml LPS (E. coli serotype 055:B5; Sigma) into
the
medium specified above except of containing 5% heat inactivated FBS. The
indicated
concentrations of the different peptides were added 30 min after addition of
LPS. The
cell supernatants were collected after 6 hours of incubation, centrifuged and
analyzed
for TNF-a production by ELISA (R&D Systems).
The results (Figure 7) of the experiment demonstrate that TNF-a production in
human
monocyte derived macrophages is significantly down regulated by the peptides.
CA 02703894 2010-04-28
WO 2009/062898 PCT/EP2008/065186
24
Example 8. Antimicrobial assay
Arg-Arg-Arg-Arg-Arg-Arg- or Arg-Arg-Arg-Arg-Arg- containing peptides (Table 4)
have
been analysed by an antimicrobial assay using E.coli, S.aureus and P.
aeruginosa as
test microorganisms.
Cells were suspended in 1 % Brain-heart infusion medium (BHI)(Difco, USA). The
concentration of bacterial cells was spectrophotometrically adjusted. Peptides
serially
diluted in 1 % BHI by twofold steps were added in duplicate to the wells of a
microtiterplate (100 l per well). The bacterial solutions were added in 5 l
volumes to
give a final concentration of approximately 5 x 105 cells per ml. The
concentration of
the stock solution was always checked by viable counts. The microtiterplate
was
incubated at 37 C for two hours. Five l were taken from each well and added
as a
drop onto a blood agar plate and incubated over night at 37 C.
The concentration of peptide causing a 99% reduction of the inoculum was
defined as
the MMC99.
Table 4
MMC99, g/ml
peptide S. aureus E. coli P. aeruginosa
PXL11 6.3 1.6 3.1
PXL12 6.3 1.6 3.1
PXL13 6.3 1.6 6.3
PXL15 6.3 1.6 3.1
HLBDarglrak 6.3 3.1 6.3
